Mineralys Therapeutics prepares for potential FDA approval of Lorundrostat with PDUFA target of December 22, 2026

Mineralys Therapeutics, in its Q3 2026 earnings call, said it is preparing for potential FDA approval of Lorundrostat, with a PDUFA target date of December 22, 2026, to address unmet needs in uncontrolled and resistant hypertension.

Detected & updated continuously · Source: Nebula